CapitalBio Corporation
CapitalBio Corporation
Company: CapitalBio Corporation Group Co., Ltd.
Legal representative: Mr. Cheng
Phone: 010-80726868
Brand birthplace: Beijing
Brand establishment time: 2000
Main Products: Stem Cells
Founded in 2000, under Tsinghua Holdings, a life science research and health industry enterprise, it creates a large health industry section integrating health products/health management and medical rehabilitation.
CapitalBio Corporation Group Co., Ltd. was supported by the leaders of the State Council, the Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Education, the Ministry of Health, and Beijing on September 30, 2000, and supported by Tsinghua University, united with Huazhong University of Science and Technology, the Chinese Academy of Medical Sciences, and Military Medicine. The Academy of Sciences was registered and established as a state-owned innovative high-tech enterprise in the life science research and health industry. The company is headquartered in Beijing, with more than 2,000 employees and more than 100,000 square meters of research and development, production, operation and service bases.
The company uses biochips as its core technology platform, has a complete medical industry chain integrating R&D, production, sales and the services of a national third-party independent medical laboratory, and responds to the national health policy of “prevention first”, combining modern medicine with Traditional Chinese medicine is closely integrated to create a large health industry section integrating health products, health management and medical rehabilitation. So far, CapitalBio Corporation has formed large-scale industrialization bases in Beijing, Shanghai, Chongqing, Chengdu, etc., and formed an industrialization platform with Beijing Boao Jingdian Biotechnology Co., Ltd. as the core.
Since its establishment 18 years ago, CapitalBio Corporation has successfully developed biochips and related reagents and consumables, instruments and equipment, software databases, life science services, clinical laboratory services, health management, etc., relying on the strong R&D capabilities of Tsinghua University and the Beijing National Engineering Research Center for Biochips. A series of dozens of products and services with independent intellectual property rights. The company has successively obtained ISO9001, ISO13485, ISO14000, ISO18000, ISO27000 quality management system certifications issued by TÜV Rheinland in Germany, the American Histocompatibility and Genetics Association (ASHI) certification and the China National Accreditation Service for Conformity Assessment laboratory certification. Its products have obtained more than 100 domestic and foreign certifications such as CFDA, CE, GS, CB. So far, CapitalBio Corporation has obtained more than 300 patent authorizations worldwide, with a high patent conversion rate.
Because of its excellent R&D, production, marketing and service teams, as well as the biochip technology platform and high-standard quality assurance system, CapitalBio Corporation has established strategic cooperation with nearly 100 domestic top-tier hospitals, universities, public security and judicial institutions, and also cooperated with Roche International life sciences and medical diagnostics companies such as Applied Science, Roche Diagnostics, Angfei, Thermoelectricity, etc. have established partnerships. Products and services are exported to more than 30 countries and regions including North America, Europe, and Asia. Among them, diagnostic biochips and related instrument products have entered hundreds of hospitals in the UK, Germany, Sweden, Italy, Spain, Austria, Switzerland, Portugal, Finland, Denmark, Japan, Singapore and other countries.
